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Guinea pigsThe lack of an efﬁcient vaccine against tuberculosis is still one of the major problems threatening global
human health. In previous work we showed that expression of the protective antigen MPT64 on the
surface of Mycobacterium bovis BCG, the only approved vaccine against tuberculosis, strongly improved
its immunogenicity and protective potential in mice. In this work we demonstrate that the same recom-
binant strain is able to induce better protection than wild type BCG also in guinea pigs preventing
Mycobacterium tuberculosis dissemination and lung pathology, making this strain a strong candidate for
further testing.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is still one of the main scourges of human
kind with about 9 million new cases of active disease and 1.5 mil-
lion deaths each year [1]. Even though TB is a curable disease,
treatment is long with patient compliance challenging, especially
in developing countries where the infection is more diffused,
boosting the emergence of strains resistant to the main anti-
tubercular drugs [2]. The only approved vaccine against TB,
Mycobacterium bovis BCG, protects against the most severe forms
of extrapulmonary TB in infants, but its efﬁcacy in preventing pul-
monary disease in adults is poor [3]. For this reason, the develop-
ment of a new vaccine against TB is one of the main challenges
to stop the TB pandemic [4]. Given that it prevents severe disease
in children, the use of BCG cannot be discontinued for ethical rea-
sons, so any new vaccination strategy must incorporate BCG or an
improved alternative e.g. recombinant BCG (rBCG) [5].
Since the mycobacterial surface is an excellent adjuvant, we
hypothesized that expressing an antigen in its context could dra-
matically increase immunogenicity. Consequently, we developed
a system to express proteins on the surface of BCG [6]. This is based
on the PE domain of PE_PGRS33, recently identiﬁed as a functionaldomain able to drive the localization of protein sequences fused
at its N-terminus on the mycobacterial outer membrane [7].
We used this system to express MPT64, a protective antigen of
Mycobacterium tuberculosis normally absent in BCG, on its surface
and demonstrated increased protection and immunogenicity com-
pared to parental strain following vaccination and challenge of
immunized mice with virulent M. tuberculosis [8]. Moreover,
homologous boosting resulted in a heightened degree of protection
of mice immunized with this HPE-DMPT64-BCG strain [9].
In this paper we further characterize the protective potential of
the HPE-DMPT64-BCG strain in guinea pigs, by demonstrating
improved protection of vaccinated animals from infection through
surface expression of MPT64.
2. Materials and methods
2.1. Bacteria
The M. tuberculosis H37Rv (National Collection of Type Cultures
(NCTC) 7416) challenge stock was generated from a chemostat
grown to steady state in a deﬁned medium which has been
described previously [10].
2.2. Vaccination
Three groups of 8 Dunkin–Hartley guinea pigs, (speciﬁc patho-
gen-free, 250–300 g), obtained from a commercial supplier
30 S.O. Clark et al. / Trials in Vaccinology 4 (2015) 29–32(Harlan, UK), were inoculated subcutaneously with 5  104 CFU of
HPE-DMPT64-BCG (rBCG expressing the PE_MPT64 chimera on
its surface) [8] or BCG Danish 1331 (Statens Serum Institute,
Copenhagen, Denmark), or were unvaccinated. Individual animals
were identiﬁed using subcutaneously implanted microchips
(PLEXX BV, The Netherlands). Guinea pig experimental work was
conducted according to UK Home Ofﬁce legislation for animal
experimentation and was approved by the local ethical review
process.
2.3. Aerosol challenge
Animals were infected with a low aerosol dose (10–50 CFU
retained in the lung) of M. tuberculosis H37Rv 12 weeks after
vaccination using a Henderson apparatus in conjunction with the
AeroMP (Biaera) control unit as previously described [11,12]. The
aerosol was generated from a water suspension containing
5  106 CFU/ml.
2.4. Necropsy and bacteriological analysis
At 4 weeks post challenge, guinea pigs were killed humanely by
intraperitoneal injection of pentabarbitone (Euthatal) and a post-
mortem examination performed immediately. For each animal,
the left middle and left and right cranial and the right caudal lobes
were placed in one sterile container for bacteriology and the
remaining lobes placed in 10% neutral-buffered formalin for
histological examination. Tissues for determination of CFU were
homogenized in 5 ml of sterile distilled water using a rotating
blade macerator system (Ystral, UK). Viable counts were performed
by plating 100 ll aliquots of serial dilutions on of the macerate
onto Middlebrook 7H11 + OADC agar (BioMerieux, UK). BacterialA
B
Fig. 1. (A) Determination of CFU in M. tuberculosis-infected guinea pigs. CFU were dete
infected guinea pigs that were unvaccinated (closed circle) or vaccinated with either B
Protective efﬁcacies are expressed as total log10 bacterial counts/tissue. Groups included
efﬁcacy of HPE-DMPT64-BCG. CFU data were analyzed by non-parametric Mann–Whitne
unvaccinated or BCG control groups. A P value of <0.05 was considered signiﬁcant.load in lungs and spleen (CFU/tissue) of each group of animals
was compared to identify statistically signiﬁcant differences
between the groups.
2.5. Histopathological examination
Formalin-ﬁxed samples were processed to parafﬁn wax, cut at
3–5 lm, and stained with haematoxylin and eosin. The nature
and severity of the lesions in lungs and spleen was assessed blind
by a veterinary pathologist using a subjective scoring system.
Brieﬂy, for the spleen, a score was assigned based on number
and size of lesions, and presence of necrosis and calciﬁcation. For
the lung, each lobe was assigned a score as follows: 0-normal; 1-
very few or small lesions, 0–10% consolidation; 2-few or small
lesions, 10–20% consolidation; 3-medium sized, 20–33% consol-
idation; 4-moderate sized lesions, 33–50% consolidation; 5–50–
80% consolidation; extensive pneumonia; >80% consolidation; plus
number of foci of necrosis. Scores from each lobe were combined. A
mean score from lung lobe and from spleen was calculated for each
group. Group mean differences were compared to subcutaneous
BCG Danish and unvaccinated control groups. A reduction in con-
solidation, foci of necrosis, and foci of calciﬁcation (spleen) in the
vaccinated animals when compared with the control groups was
considered a protective effect of the vaccine. However, the scores
are a product of a subjective scoring system and, therefore, are
not regarded as numerical data suitable for statistical analysis.
2.6. Statistics
Statistical analysis was performed with Minitab software ver-
sion 15. The CFU data were analyzed by non-parametric Mann–
Whitney test comparisons to compare median values of thermined in lung (left) and spleen (right) homogenates derived from M. tuberculosis-
CG (open circle) or HPE-DMPT64-BCG (closed square) as indicated on the x-axis.
eight guinea pigs. Each symbol represents one guinea pig. (B) Table summarising the
y test comparisons to compare median values of the vaccine groups with either the
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A P value of <0.05 was considered signiﬁcant.3. Results and Discussion
Fig. 1A shows the bacterial burden in lung and spleen of the
three groups of guinea pigs. Both vaccinated groups showed a sig-
niﬁcant reduction of CFUs in lung and spleen compared to the
unvaccinated group. While protection measured in the lung was
equivalent for the two vaccines, the protective effect in the spleenFig. 2. Guinea pig histopathology presented as a group mean score as stacked bars in lun
H37Rv. Histopathology was measured 4 weeks post-challenge. Black bar: consolidation
lesions were observed in the tissue section.
Fig. 3. Photomicrographs of lung sections of infected animals stained with hematoxylin
(arrows), and scattered, smaller granulomas. Calibration bar, 500 lm; (B) BCG vaccinate
bar, 500 lm; (C) the HPE-DMPT64-BCG vaccinated animal. A single, small, granuloma (ar
epithelioid macrophages with some lymphocytes. Calibration bar, 50 lm.was signiﬁcantly higher for the HPE-DMPT64-BCG strain (3.79
Log10 CFU/tissue) than that provided by wt BCG (2.95 Log10
CFU tissue) (Fig. 1B).
A reduction in the severity of microscopic changes in both lung
and spleen, was observed in both vaccinated groups. Interestingly,
even if the bacterial burden in the lung of wt BCG and HPE-
DMPT64-BCG vaccinated animals was similar, animals vaccinated
with HPE-DMPT64-BCG showed a reduced number of foci of necro-
sis in this organ. These results are in agreement with the reduced
immunopathology observed in the lung of mice, both in the acute
and chronic steps of M. tuberculosis infection, in HPE-DMPT64-BCGg (left) and spleen (right) following low dose, aerosol challenge with M. tuberculosis
score and white bar: number of foci of necrosis/caseation score. ⁄indicates that no
and eosin. (A) Unvaccinated animal. Large granulomas, three with central necrosis
d animal. Variably sized granulomas, one with central necrosis (arrow). Calibration
row). Calibration bar, 500 lm. Inset, higher power of granuloma comprising mainly
32 S.O. Clark et al. / Trials in Vaccinology 4 (2015) 29–32vaccinated animal compared to BCG immunized mice [8], and sug-
gest that immunization with HPE-DMPT64-BCG may result not
only in an improved bacterial killing but also in a dampening of
the host immune responses classically associated with disease
and ultimately TB transmission [13]. The reduced pathology in
HPE-DMPT64-BCG vaccinated animals was even more evident in
spleen, where lesions were not observed (Figs. 2 and 3). Taken
together these results support enhanced protective effect elicited
by the HPE-DMPT64-BCG compared to BCG in the guinea pig model
of TB.
The reduced bacterial burden and absence of lesions in the
spleen of HPE-DMPT64-BCG vaccinated animals compared to those
immunized with wt BCG, suggests that the immune response eli-
cited by the former was more effective in preventing bacterial dis-
semination. Similarly, homologous boosting of mice immunized
with HPE-DMPT64-BCG resulted in a speciﬁc reduction in CFUs in
the spleen [9]. In mice, the superior protection afforded by HPE-
DMPT64-BCG over BCG, or a recombinant BCG strain expressing
MPT64 in the cytosol, was associated with the ability to elicit
MPT64-speciﬁc IFN-c secreting cells carrying a speciﬁc T cell reper-
toire [8]. Hence, it is possible that also in guinea pigs these MPT64-
speciﬁc T lymphocytes may warrant enhanced anti-TB activity.
Vaccines capable of eliciting an immune response that can more
effectively control bacterial dissemination could be of relevance
in humans, where dissemination from the site of primary infection
is a key step in TB pathogenesis following primary infection [2,14]
and during latent TB infection, when ‘‘scouting’’ bacilli arising from
the dormant reservoir may actively replicate and promote active
disease [15,16].
The reduced pathology observed in the lung of HPE-DMPT64-
BCG immunized animals compared to those vaccinated with BCG
conﬁrms previous observation in mice [8], further highlighting
the enhanced protective activity afforded by this strain.
Although many new live attenuated vaccines have been devel-
oped and tested in preclinical animal models, very fewwere able to
consistently provide enhanced protection over BCG, which is used
as the gold standard [17]. The results obtained in mice and guinea
pigs for the HPE-DMPT64-BCG strain are very promising, making it
a candidate for further testing. Moreover, it is worth noting that
PE_MPT64 could be expressed on the surface of other rBCG strains,
such as the BCG ureC hly+ strain [18], opening the possibility to fur-
ther enhance the anti-TB immunity elicited by these recombinant
BCG strains.
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